Recent Posts
- Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023
- Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
- Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
- Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
- Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women’s Sexual Health Annual Meeting 2023
Archives
- March 2023
- February 2023
- December 2022
- November 2022
- September 2022
- August 2022
- June 2022
- April 2022
- February 2022
- December 2021
- November 2021
- June 2021
- May 2021
- April 2021
- January 2021
- December 2020
- October 2020
- September 2020
- July 2020
- June 2020
- December 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
Recent Comments